Advertisement

Topics

Actelion Pharmaceuticals US, Inc. Company Profile

08:06 EST 23rd November 2017 | BioPortfolio

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer® (bosentan), an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer® through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2000 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®).


News Articles [483 Associated News Articles listed on BioPortfolio]

Actelion receives FDA approval for 32mg Tracleer to treat paediatric PAH patients

Actelion Pharmaceuticals US, a Janssen Pharmaceutical Company of Johnson & Johnson, has received US Food and Drug Administration (FDA) approval for Tracleer (bosentan) to be used in paediatric patient...

SMC bars access to Actelion’s Uptravi on NHS Scotland

Actelion says it is disappointed with a decision by Scottish cost regulators to refuse NHS funding for pulmonary arterial hypertension drug Uptravi.

Actelion’s Reincarnation Comes Out Swinging with Phase II Success in Insomnia

Actelion’s successor Idorsia reported its candidate for insomnia met the primary endpoint in Phase II and will advance to Phase III. In its first report from the clinic last Friday, Idorsia anno...

Christoph Schmidt, Corporate VP Global Head of Commercial Excellence, Actelion Pharmaceuticals

Christoph Schmidt, Corporate VP Global Head of Commercial Excellence, Actelion Pharmaceuticals

Actelion-Aktien werden per 7. November 2017 dekotiert - letzter Handelstag 6.11.

Zürich (awp) - Die SIX Swiss Exchange hat das Datum der schon länger erwarteten Dekotierung der Actelion-Aktien festgelegt. Die Aktie wird demnach per 7. November 2017 dekotiert, der letzte Handels....

Zukauf und neue Krebsmittel kurbeln das Geschäft an: Die Übernahme von Actelion wirkt sich bereits im ...

Die Übernahme von Actelion wirkt sich bereits im ersten Quartal nach Abschluss der Transaktion positiv auf die Zahlen von Johnson & Johnson aus. Der Pharmakonzern überrascht die Analysten. An der B....

FDA Approves First Medication for Pediatric PAH, Bosentan

The FDA has approved bosentan (Tracleer, Actelion Pharmaceuticals) for children aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension. FDA Approvals

Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017

Actelion Pharmaceuticals Ltd / Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017 . Processed and transmitted by Nasdaq Corporate Solutions. T...

Drugs and Medications [272 Associated Drugs and Medications listed on BioPortfolio]

Ventavis [Actelion Pharmaceuticals US, Inc.]

These highlights do not include all the information needed to use VENTAVIS safely and effectively. See full prescribing information for VENTAVIS. VENTAVIS (iloprost) inhalation solution Initial U.S. A...

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash

Veletri [Actelion Pharmaceuticals US, Inc.]

These highlights do not include all the information needed to use VELETRI safely and effectively. See full prescribing information for VELETRI. VELETRI (epoprostenol) for Injection Initial U.S. Approv...

Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

PubMed Articles [121 Associated PubMed Articles listed on BioPortfolio]

Announcing the 2017 Pharmaceuticals Travel Award for Young Post-Doctoral Researchers.

Last year, for the first time in its history, our Journal was able to offer a travel grant of 800 CHF to a young researcher in the field of medicinal chemistry.

Suspended solids moderate the degradation and sorption of waste water-derived pharmaceuticals in estuarine waters.

This study focuses on the fate of pharmaceuticals discharged into an estuarine environment, particularly into the Turbidity Maximum Zone (TMZ). Batch experiments were set up to investigate the factors...

Chiral pharmaceuticals: A review on their environmental occurrence and fate processes.

More than 50% of pharmaceuticals in current use are chiral compounds. Enantiomers of the same pharmaceutical have identical physicochemical properties, but may exhibit differences in pharmacokinetics,...

Comparative study on pharmaceuticals adsorption in reclaimed water desalination concentrate using biochar: Impact of salts and organic matter.

The synergistic impact of salts and organic matter on adsorption of ibuprofen and sulfamethoxazole by three types of biochar and an activated carbon was investigated using reclaimed water reverse osmo...

Effects of exposure to pharmaceuticals (diclofenac and carbamazepine) spiked sediments in the midge, Chironomus riparius (Diptera, Chironomidae).

Human and veterinary pharmaceuticals and degradation products are continuously introduced into the environment. To date, there is a lack of information about the effects of pharmaceuticals in spiked t...

Clinical Trials [208 Associated Clinical Trials listed on BioPortfolio]

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects Under Fasting Condition

- Objective: - To compare the rate and extent of absorption of Citalopram Hydrobromide Tablets 40 mg: Test Product: Citalopram Hydrobromide Tablets 40 mg manufactured b...

Bioequivalence Study of Hydrochlorothiazide 50mg Tablets Under Fasting Conditions

To compare the single-dose oral bioavailability of hydrochlorothiazide 50 mg tablet of Ohm Laboratories (A subsidiary of Ranbaxy pharmaceuticals USA) with hydrochlorothiazide 50 mg tablet ...

Companies [1292 Associated Companies listed on BioPortfolio]

Actelion Pharmaceuticals Ltd

Actelion aims to discover or in-license and develop a steady stream of new products as revenue sources, based on first-in class small molecule compounds. In doing so, Actelion is focussing on innovati...

Actelion Pharmaceuticals US, Inc.

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer® (bosentan), an orally available dual endothelin receptor a...

Actelion

Actelion Ltd, a biopharmaceutical company headquartered in Allschwil / Basel, Switzerland, is a leading player in innovative science related to the endothelium - the single layer of cells separating e...

Maelor Pharmaceuticals Ltd.

Maelor is a publicly listed (AIM:MLR) specialist critical care pharmaceuticals and devices company. The Company has developed an expertise in bringing both pharmaceuticals and devices to the market as...

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...

More Information about "Actelion Pharmaceuticals US, Inc." on BioPortfolio

We have published hundreds of Actelion Pharmaceuticals US, Inc. news stories on BioPortfolio along with dozens of Actelion Pharmaceuticals US, Inc. Clinical Trials and PubMed Articles about Actelion Pharmaceuticals US, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Actelion Pharmaceuticals US, Inc. Companies in our database. You can also find out about relevant Actelion Pharmaceuticals US, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record